Summit Therapeutics (SMMT) Total Debt (2019 - 2024)

Summit Therapeutics (SMMT) has 3 years of Total Debt data on file, last reported at $100.0 million in Q1 2024.

• Quarterly Total Debt changed 0.0% year-over-year to $100.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $100.0 million (changed 0.0% YoY) and the FY2023 annual result came in at $100.0 million, down 79.78% from the prior year.
• Total Debt was little changed at $100.0 million in Q1 2024, from $100.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $494.5 million in Q4 2022 to a low of $25.1 million in Q1 2022.
• A 3-year average of $135.0 million and a median of $100.0 million in 2023 frame the typical range for Total Debt.
• The widest YoY moves for Total Debt: up 299.12% in 2023, down 79.78% in 2023.
• Tracing SMMT's Total Debt over 3 years: stood at $494.5 million in 2022, then tumbled by 79.78% to $100.0 million in 2023, then changed by 0.0% to $100.0 million in 2024.
• The last three Total Debt figures came in at $100.0 million (Q1 2024), $100.0 million (Q4 2023), and $100.0 million (Q2 2023), per Business Quant data.